{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:57Z","timestamp":1790456097074,"version":"4.1.0"},"reference-count":39,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2024.1904","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:35:41Z","timestamp":1733398541000},"source":"Crossref","is-referenced-by-count":12,"title":["Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes"],"prefix":"10.3892","volume":"22","author":[{"given":"Xiuying","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Beijing Aerospace General Hospital, Beijing 100076, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanming","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Beijing Aerospace General Hospital, Beijing 100076, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Aerospace General Hospital, Beijing 100076, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"key20250110112622_b1-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"key20250110112622_b2-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"key20250110112622_b3-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.clinthera.2017.01.015","article-title":"Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computed tomography and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"39","author":"Yabiku","year":"2017","journal-title":"Clin Ther"},{"key":"key20250110112622_b4-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"key20250110112622_b5-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"key20250110112622_b6-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review","volume":"10","author":"Raj","year":"2019","journal-title":"World J Diabetes"},{"key":"key20250110112622_b7-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"key20250110112622_b8-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: A review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"key20250110112622_b9-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","article-title":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","volume":"11","author":"Bays","year":"2017","journal-title":"J Clin Lipidol"},{"key":"key20250110112622_b10-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20250110112622_b11-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats","volume":"20","author":"Jaikumkao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"key20250110112622_b12-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250110112622_b13-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45 (Suppl 1)","year":"2022","journal-title":"Diabetes Care"},{"key":"key20250110112622_b14-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"key20250110112622_b15-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"key20250110112622_b16-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"key20250110112622_b17-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"key20250110112622_b18-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3803\/EnM.2018.33.3.387","article-title":"Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease","volume":"33","author":"Choi","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"key20250110112622_b19-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-019-00785-6","article-title":"Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"39","author":"Arase","year":"2019","journal-title":"Clin Drug Investig"},{"key":"key20250110112622_b20-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"key20250110112622_b21-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"key20250110112622_b22-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-lift trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"key20250110112622_b23-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"key20250110112622_b24-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"key20250110112622_b25-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol Res"},{"key":"key20250110112622_b26-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"key20250110112622_b27-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1042\/CS20190863","article-title":"Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats","volume":"133","author":"Swe","year":"2019","journal-title":"Clin Sci (Lond)"},{"issue":"589273","key":"key20250110112622_b28-BR-22-2-01904","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"120956","key":"key20250110112622_b29-BR-22-2-01904","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci"},{"issue":"106730","key":"key20250110112622_b30-BR-22-2-01904","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet-induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"key20250110112622_b31-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"key":"key20250110112622_b32-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"300060520931609","key":"key20250110112622_b33-BR-22-2-01904","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520931609","article-title":"The role of oxidation of low-density lipids in pathogenesis of osteoarthritis: A narrative review","volume":"48","author":"Hashimoto","year":"2020","journal-title":"J Int Med Res"},{"key":"key20250110112622_b34-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/HEP.0000000000000330","article-title":"Intermittent fasting-the future treatment in NASH patients?","volume":"78","author":"Minciuna","year":"2023","journal-title":"Hepatology"},{"key":"key20250110112622_b35-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"key20250110112622_b36-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/hepr.13304","article-title":"Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus","volume":"49","author":"Akuta","year":"2019","journal-title":"Hepatol Res"},{"issue":"109791","key":"key20250110112622_b37-BR-22-2-01904","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"key20250110112622_b38-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","article-title":"Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes","volume":"56","author":"Tosaki","year":"2017","journal-title":"Intern Med"},{"key":"key20250110112622_b39-BR-22-2-01904","doi-asserted-by":"publisher","first-page":"399","DOI":"10.12669\/pjms.35.2.21","article-title":"Eff\u0131cacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin","volume":"35","author":"Sertbas","year":"2019","journal-title":"Pak J Med Sci"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:26:28Z","timestamp":1736501188000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2024.1904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2024.1904","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"article-number":"26"}}